Sieczkarski Sara B, Brown H Alex, Whittaker Gary R
Microbiology and Immunology, Cornell University, Ithaca, New York 14853, USA.
J Virol. 2003 Jan;77(1):460-9. doi: 10.1128/jvi.77.1.460-469.2003.
Many viruses take advantage of receptor-mediated endocytosis in order to enter target cells. We have utilized influenza virus and Semliki Forest virus (SFV) to define a role for protein kinase C betaII (PKCbetaII) in endocytic trafficking. We show that specific PKC inhibitors prevent influenza virus infection, suggesting a role for classical isoforms of PKC. We also examined virus entry in cells overexpressing dominant-negative forms of PKCalpha and -beta. Cells expressing a phosphorylation-deficient form of PKCbetaII (T500V), but not an equivalent mutant form of PKCalpha, inhibited successful influenza virus entry-with the virus accumulating in late endosomes. SFV, however, believed to enter cells from the early endosome, was unaffected by PKCbetaII T500V expression. We also examined the trafficking of two cellular ligands, transferrin and epidermal growth factor (EGF). PKCbetaII T500V expression specifically blocked EGF receptor trafficking and degradation, without affecting transferrin receptor recycling. As with influenza virus, in PKCbetaII kinase-dead cells, EGF receptor was trapped in a late endosome compartment. Our findings suggest that PKCbetaII is an important regulator of a late endosomal sorting event needed for influenza virus entry and infection.
许多病毒利用受体介导的内吞作用进入靶细胞。我们利用流感病毒和Semliki森林病毒(SFV)来确定蛋白激酶CβII(PKCβII)在内吞运输中的作用。我们发现,特异性PKC抑制剂可阻止流感病毒感染,提示PKC的经典亚型发挥了作用。我们还检测了在过表达PKCα和β的显性负性形式的细胞中的病毒进入情况。表达PKCβII磷酸化缺陷形式(T500V)的细胞,而非PKCα的等效突变形式,抑制了流感病毒的成功进入——病毒积聚在晚期内体中。然而,据信从早期内体进入细胞的SFV不受PKCβII T500V表达的影响。我们还检测了两种细胞配体转铁蛋白和表皮生长因子(EGF)的运输。PKCβII T500V表达特异性地阻断了EGF受体的运输和降解,而不影响转铁蛋白受体的循环利用。与流感病毒一样,在PKCβII激酶失活的细胞中,EGF受体被困在晚期内体区室中。我们的研究结果表明,PKCβII是流感病毒进入和感染所需的晚期内体分选事件的重要调节因子。